|
Title
|
|---|
|
Additional Risk Minimization Measure Enbrel |
- 20-Vgu-Metformin
- Additional Risk Minimization Measure Enbrel
- Additional Risk Minimization Measure Mabthera
- Alert- Substandard Paracetamol Suspension
- Amedin Recall Letter
- Association Of Ibandronic Acid And Anaphylaxis (Anaphylactic Reaction, Anaphylactic Shock)
- Azithromycin And Cardiovascular Risks
- Boxed Warning - Exjade (Deferasirox)
- DHCP Lettre Plaquenil - Ghana Final
- DHPL Ketoconazole For Publication0001
- DHPL On Rare Events Of Thrombosis And Thrombocytopenia Following Vaccination With Covid-19 Vaccine Astrazeneca
- Diclofenac And Risk Of Cardiovascular Events (Heart Attack And Stroke)
- FDA DHCP Letter Valproate Gs
- FDA_Gh Valproate Guide For Healthcare Professionals
- Gadolinium Dhcp Letter0001
- Losartan DHCP New
- Oral Ketoconazole And The Risk Of Severe Liver Injury, Adrenal Gland Problems And Harmful Drug Interactions
- Over-The-Counter Cold And Cough Preparations In Childrenfollow-Up To An Earlier Communication
- Paracetamol And The Risk Of Rare But Serious Skin Reactions
- Rare but serious allergic reactions
- Reporting Incidents Of Therapeutic Ineffectiveness As Adverse Events
- Reporting Medical Errors
- Restrictions On The Use Of Codeine As An Analgesic In Children And Adolescents
- Review Of The Safety Of Metamizole Sodium
- Safety Alert-Ibrance
- Safety Information On The Risk Of Development Of Anaphylactic Reactions To General Anaesthesia With Neuromuscular Blocking Agents (NMBAa)
- Safety Of (Dextro)Propoxyphene-Containing Products
- Suspected Oral Quinine Sulphate Induced Bleeding And Incomplete Abortion
- Update on safety of pioglitazone
- Vgu 0184 Safety Alert Recall Of Pfizers Accupril (Quinapril Hydrochloride)
- Vgu 0449 Substandard (Contaminated) Paediatric Medicines Identified In Who Region Of Africa
- Vgu-23-0125 Strengthened Risk Management For Sodium Valproate And Mandated Changes To The Product Information
- Vgu-23-0224 Fluoroquinolone Antibiotics Reminder Of Measures To Reduce The Risk Of Long-Lasting, Disabling And Potentially Irreversible Side Eff
- Vgu-23-0306 New Safety Measures On The Use Of Isotretinoin
- 17-700 Dhpl Acei - Dear Healthcare Professional
- 18-192-Potential For Increased Ltr With Clarithromycin
- 18-293-Suspension Of Mah For Cccs-Signed
